This is the authors' abstract. We don't add key points for this paper.
Background: Emerging evidence links gut microbiota to tumorigenesis via immune modulation, though subtype-specific microbial signatures in B-cell lymphomas remain unclear. This study explores microbiota-immune interactions across lymphoma subtypes to inform microbiota-targeted therapies. Methods: Twenty-seven treatment-naive B-cell lymphoma patients (8 DLBCL, 5 SLL, 5 FL, 7 MZL, 2 WM) and 20 HCs were enrolled. Fecal 16S rDNA sequencing, flow cytometry for immune cell subsets, and ELISA for cytokines/immunoglobulins were performed. Microbiota differences and correlations with immune parameters were analyzed. Small B-cell lymphoma and DLBCL exhibited distinct flora: Selenomonadaceae/Actinobacteriota dominated in DLBCL, while Enterobacteriaceae prevailed in small B-cell subtypes. Correlations showed Enterobacteriaceae positively linked to Th cells/PCT/TNF and negatively to IL-10 in small B-cell lymphoma; Actinobacteriota correlated with B/T cells/Treg/IFN-β and inversely with IL-2/IL-4/CD8+T cells. Conclusions: This study identifies distinct patterns of gut microbiota dysbiosis across B-cell lymphoma subtypes and explores their correlations with host immune parameters.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: